SC Filed 2021-11-12 Event — SEC 0000947871-21-001178 →

ORBIMED ADVISORS LLC → ALPINE IMMUNE SCIENCES, INC.

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 2/100 · Filer 90d Win Rate: 25% · Hist. 90d Edge: -5.4%

Filer track record (12 filings): 25% 90d win rate, +0.0% 90d edge

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

16 13D/G filings on this issuer

15 other filings besides this one

Filer Track Record

145 filings by this filer

144 other filings in the data moat

Short Interest

—

Not in latest FINRA snapshot

Other 13D/G Filings on ALPINE IMMUNE SCIENCES, INC.

Filed	Form	Filer	Stake	Shares
2022-09-27	SC	Decheng Capital China Life Sciences USD Fund III, L.P.	—	—	view →
2022-09-27	SC	ORBIMED ADVISORS LLC	—	—	view →
2022-09-27	SC	Alpine ImmunoSciences, L.P.	—	—	view →
2022-02-15	SC	Frazier Life Sciences VIII, L.P.	—	—	view →
2021-09-21	SC	Frazier Life Sciences VIII, L.P.	—	—	view →
2021-09-21	SC	Decheng Capital China Life Sciences USD Fund III, L.P.	—	—	view →
2021-09-21	SC	Alpine ImmunoSciences, L.P.	—	—	view →
2020-12-22	SC	Alpine ImmunoSciences, L.P.	—	—	view →
2020-08-03	SC	Alpine ImmunoSciences, L.P.	—	—	view →
2020-08-03	SC	Decheng Capital China Life Sciences USD Fund III, L.P.	—	—	view →
2019-01-23	SC	Alpine ImmunoSciences, L.P.	—	—	view →
2019-01-23	SC	ORBIMED ADVISORS LLC	—	—	view →
2019-01-23	SC	Frazier Life Sciences VIII, L.P.	—	—	view →
2018-01-26	SC	ORBIMED ADVISORS LLC	—	—	view →
2018-01-26	SC	ORBIMED ADVISORS LLC	—	—	view →

Other Filings by ORBIMED ADVISORS LLC

Filed	Form	Issuer	Stake	Shares
2026-10-08	SCHEDULE 13D/A	ArriVent BioPharma, Inc.	5.80%	2,875,962	view →
2026-10-02	SCHEDULE 13D	ADARx Pharmaceuticals, Inc.	14.00%	14,913,764	view →
2026-09-25	SCHEDULE 13D	Electra Therapeutics, Inc.	11.00%	6,885,170	view →
2026-09-10	SCHEDULE 13D/A	Braveheart Bio, Inc.	13.50%	12,175,159	view →
2026-08-18	SCHEDULE 13D	BlossomHill Therapeutics, Inc.	8.90%	2,714,279	view →
2026-08-18	SCHEDULE 13D	Braveheart Bio, Inc.	17.20%	12,175,159	view →
2026-08-10	SCHEDULE 13D/A	MBX Biosciences, Inc.	—	3,074,853	view →
2026-08-05	SCHEDULE 13D	Yarrow Bioscience, Inc.	9.97%	266,306	view →
2026-07-29	SCHEDULE 13D	Scribe Therapeutics, Inc.	7.20%	1,348,825	view →
2026-07-20	SCHEDULE 13D/A	Q32 Bio Inc.	—	4,127,987	view →
2026-06-24	SCHEDULE 13D/A	Enliven Therapeutics, Inc. ELVN	—	6,774,507	view →
2026-06-17	SCHEDULE 13D/A	Enliven Therapeutics, Inc. ELVN	10.93%	7,634,630	view →
2026-06-15	SCHEDULE 13D/A	Shattuck Labs, Inc. STTK	—	9,021,127	view →
2026-06-01	SCHEDULE 13D/A	Q32 Bio Inc. QTTB	—	4,127,987	view →
2026-04-10	SCHEDULE 13D/A	Adicet Bio, Inc. ACET	8.80%	844,787	view →
2026-01-27	SCHEDULE	Corvus Pharmaceuticals, Inc. CRVS	10.30%	8,609,091	view →
2025-10-10	SCHEDULE	Adicet Bio, Inc. ACET	9.60%	14,772,598	view →
2025-09-30	SCHEDULE	MBX Biosciences, Inc. MBX	9.00%	4,002,887	view →
2025-07-21	SCHEDULE	Passage BIO, Inc. PASG	7.82%	243,878	view →
2025-05-14	SCHEDULE	Corvus Pharmaceuticals, Inc. CRVS	12.20%	9,785,423	view →

Showing 20 of 144

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →